Episodic pain is a common problem for patients with advanced cancer and is often difficult to manage successfully. In this article, the daily variations in cancer-related episodic pain in a patient with metastatic lung cancer are described. The definition, etiology, prevalence, and pharmacological management of episodic pain are also reviewed.
Banning PJF, Sjogren P, Henriksen H: Pain caused in 200 patients referred to a multidisciplinary cancer pain clinic. Pain. 1991; 47: 129-134.
4.
Bruera E, Fainsinger R, MacEachern T, et al.: The use of methylphenidate in patients with incident cancer pain receiving regular opiates: A preliminary report. Pain. 1992; 50: 75-77.
5.
Mercadante S, Maddaloni S, Roccella S, et al.: Predictive factors in advanced cancer pain treated only by analgesics. Pain. 1992; 50: 151-155.
6.
Ashby MA, Fleming BG, Brooksbank M, et al.: Description of a mechanistic approach to pain management in advanced cancer: Preliminary report. Pain. 1992; 51: 153-161.
7.
Grond S, Zech D, Diefenbach C, et al.: Assessment of cancer pain: A prospective evaluation in 2,266 cancer patients referred to a pain service. Pain. 1996; 64(1): 107-114.
8.
Fine PG, Busch MA: Characterization of breakthrough pain by hospice patients and their caregivers. J Pain & Symptom Management. 1998; 16: 179-183.
9.
Petzke F, Radbruch L, Zech D, et al.: Temporal presentation of chronic cancer pain: Transitory pains on admission to a multidisciplinary pain clinic. J Pain & Symptom Management. 1999; 17: 391-401.
10.
Caraceni A, Portenoy RK: An international survey of cancer pain characteristics and syndromes: IASP Task Force on Cancer Pain, International Association for the Study of Pain. Pain. 1999; 82(3): 263-274.
11.
Portenoy RK, Payne D, Jacobsen P: Breakthrough pain: Characteristics and impact in patients with cancer pain. Pain. 1999; 81(1-2): 129-134.
12.
Zeppetella G, O’Doherty C, Collins S: Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain & Symptom Management. 2000; 20(2): 87-92.
13.
Swanwick M, Haworth M, Lennard RF: The prevalence of episodic pain in cancer: A survey of hospice patients on admission. Palliative Medicine. 2001; 15(1): 9-18.
14.
Portenoy RK: Treatment of temporal variations in chronic cancer pain. Semin Oncol. 1997; 24(5)(suppl. 16): S16-7-S16-12.
15.
McQuay HJ, Carroll D, Moore RA: Radiotherapy for painful bone metastases: A systematic review. Clini Oncol. 1997; 9(3): 150-154.
16.
Eisenberg E, Berkey CS, Carr DB, et al.: Efficacy and safety of nonsteroidal anti-inflammatory drugs for cancer pain: A meta-analysis. J Clinical Oncology. 1994; 12: 2756-2765.
17.
Djulbegovic B, Wheatley K, Ross J, et al.: Bisphosphonates in multiple myeloma (Cochrane Review). In The Cochrane Library. Issue 4. Oxford: Update Software, 2001.
18.
McQuay HJ, Tramer M, Nye BA, et al.: A systematic review of antidepressants in neuropathic pain. Pain. 1996; 68: 217-227
19.
McQuay H, Carroll D, Jadad AR, et al.: Anticonvulsant drugs for management of pain: a systematic review. BMJ. 1995; 311: 1047-1052.
20.
Kalso E, Tramer MR, Moore RA, McQuay HJ: Systemic local anaesthetic type drugs in chronic pain: A qualitative systematic review. European J Pain. 1998; 2: 3-14.
21.
Hanks GW, de Conno F, Cherny N, et al.: Morphine and alternative opioids in cancer pain: The EAPC recommendations. British J Cancer. 2001; 84: 587-593.
22.
Collins SL; et al.: Peak plasma concentrations after oral morphine: A systematic review. J Pain & Symptom Management. 1998; 16: 388-402.
23.
Portenoy RK, Payne R, Coluzzi P, et al.: Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: A controlled dose titration study. Pain. 1999; 79: 303-312.
24.
Zeppetella G: Nebulized and intranasal fentanyl in the management of cancer-related breakthrough pain. Palliative Medicine. 2000; 14: 57-58.
25.
Pavis H, Wilcock A, Edgecombe J, et al.: Pilot study of nasal morphine-chitosan for relief of breakthrough pain in patients with cancer. J Pain & Symptom Management. 2002; [in press].
